Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of PF-07321332 Formulations in Healthy Adults
NCT05263895Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time and 1 more. Started Mar 2022; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05263895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263895.